Acute Effects of HIIT and MICT on Catestatin Dynamics in Young Males
Effects of Acute HIIT and MICT on Catestatin Dynamics in Sedentary Young Males: Selective Association With Post-Exercise Autonomic Recovery
2 other identifiers
interventional
20
1 country
1
Brief Summary
Physical exercise acts as a major physiological stressor that alters cardiovascular and autonomic homeostasis. Catestatin (CTS), a bioactive peptide derived from chromogranin A (CgA), acts as a potent inhibitor of catecholamine secretion and modulates autonomic cardiovascular tone. However, the acute effects of distinct exercise modalities on circulating CTS dynamics and their associations with post-exercise autonomic recovery remain unclarified. The purpose of this study is to investigate the acute responses of serum catestatin and chromogranin A to high-intensity interval training (HIIT) versus moderate-intensity continuous training (MICT) in healthy sedentary young males, and to evaluate their potential relationship with post-exercise heart rate recovery (HRR). Participants completed an initial incremental performance test followed by either a single HIIT session or a MICT session on a cycle ergometer. Serial blood samples and continuous cardiovascular measurements were obtained before, immediately after, and throughout a 60-minute post-exercise recovery period.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable healthy-volunteers
Started Oct 2025
Shorter than P25 for not_applicable healthy-volunteers
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 24, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 10, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
March 5, 2026
CompletedFirst Submitted
Initial submission to the registry
September 9, 2026
CompletedFirst Posted
Study publicly available on registry
September 15, 2026
CompletedSeptember 15, 2026
July 1, 2025
3 months
September 9, 2026
September 9, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Serum Catestatin Concentration
Serum catestatin levels measured using enzyme-linked immunosorbent assay (ELISA) to evaluate acute exercise-induced dynamic responses.
Baseline (pre-exercise), immediately post-exercise (0 min), and at 15, 30, 45, and 60 minutes post-exercise.
Secondary Outcomes (2)
Serum Chromogranin-A Concentration
Baseline (pre-exercise), immediately post-exercise (0 min), and at 15, 30, 45, and 60 minutes post-exercise.
Post-Exercise Heart Rate Recovery (HRR1 and HRR5)
At 1 minute and 5 minutes post-exercise.
Study Arms (2)
High-Intensity Interval Training (HIIT)
EXPERIMENTALParticipants completed an acute HIIT session on a cycle ergometer consisting of a 5-minute warm-up, followed by four 4-minute bouts at 85-95% of maximum heart rate (HRmax) interleaved with 3-minute active recovery periods, followed by a 5-minute cool-down.
Moderate-Intensity Continuous Training (MICT)
EXPERIMENTALParticipants completed an acute MICT session on a cycle ergometer consisting of a 5-minute warm-up, followed by 30 minutes of continuous cycling at 60-70% of maximum heart rate (HRmax), followed by a 5-minute cool-down.
Interventions
Acute bout of 4x4 min intervals at 85-95% HRmax with 3 min active recovery on a cycle ergometer.
Acute bout of continuous cycling for 30 minutes at 60-70% HRmax on a cycle ergometer.
Eligibility Criteria
You may qualify if:
- Healthy male individuals aged 18-25 years
- Body mass index (BMI) between 18.0 and 25.0 kg/m²
- Sedentary lifestyle (no regular exercise engagement within the last 3 months; \<90 min/week moderate-intensity or \<60 min/week vigorous-intensity exercise)
- Normal resting blood pressure (\<140/90 mmHg)
- Fasting plasma glucose between 60 and 100 mg/dL
- Normal resting electrocardiogram (ECG) and pulmonary function tests (FEV1/FVC \>80%)
- Signed written informed consent
You may not qualify if:
- Regular smoking or alcohol consumption
- Any current or regular medication use
- History or clinical signs of cardiovascular, respiratory, metabolic, or renal diseases
- Symptoms suggestive of cardiopulmonary/metabolic disease (chest pain, shortness of breath, dizziness, syncope, ankle edema, palpitations, intermittent claudication)
- Presence of known cardiovascular risk factors
- Iron deficiency / anemia
- Musculoskeletal limitations or contraindications to maximal cycle ergometer testing
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Firat University Medical Faculty, Department of Physiology
Elâzığ, Elâzığ, 23119, Turkey (Türkiye)
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
September 9, 2026
First Posted
September 15, 2026
Study Start
October 24, 2025
Primary Completion
January 10, 2026
Study Completion
March 5, 2026
Last Updated
September 15, 2026
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- Beginning immediately following publication with no end date.
- Access Criteria
- Data will be shared for non-commercial academic research purposes upon written request to the corresponding author.
De-identified individual participant data that underlie the results reported in this article will be shared with researchers upon reasonable request directed to the corresponding author.